Robert C Kane

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:2955-60. 2006
  2. ncbi request reprint Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
  3. ncbi request reprint Bortezomib for the treatment of mantle cell lymphoma
    Robert C Kane
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Clin Cancer Res 13:5291-4. 2007
  4. doi request reprint Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 2109, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:445-50. 2008
  5. doi request reprint The clinical significance of statistical significance
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:1129-33. 2008
  6. doi request reprint Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
  7. ncbi request reprint Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    Robert C Kane
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 8:508-13. 2003

Detail Information

Publications7

  1. ncbi request reprint United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:2955-60. 2006
    ..The FDA analysis of the trial data and bortezomib's regulatory development are summarized here...
  2. ncbi request reprint Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
    ..S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC)...
  3. ncbi request reprint Bortezomib for the treatment of mantle cell lymphoma
    Robert C Kane
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Clin Cancer Res 13:5291-4. 2007
    ..To describe the Food and Drug Administration review and marketing approval considerations for bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma...
  4. doi request reprint Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 2109, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:445-50. 2008
    ..For this uncommon but serious complication of anthracycline therapy, the need for surgical intervention was 1.7% with this regimen...
  5. doi request reprint The clinical significance of statistical significance
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:1129-33. 2008
    ....
  6. doi request reprint Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
    ..Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
  7. ncbi request reprint Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    Robert C Kane
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 8:508-13. 2003
    ..This report highlights the FDA analysis supporting the accelerated approval...